Shibutani Hiroshi Chris 4

What Happened Hiroshi Chris Shibutani, EVP and Chief Strategy Officer of Bristol Myers Squibb (BMY), was granted two sets of performance-based derivative awards on 2026-03-10: 7,837 market share units and 11,755 performance share units, for a total of 19,592 units. The awards are recorded at $0.00 per unit (no cash paid) and are coded as grants/awards (transaction code A). These are not open-market purchases or sales but equity compensation subject to performance and vesting conditions.

Key Details

• Transaction date: 2026-03-10; Form 4 filed 2026-03-12 (appears timely).
• Award amounts: 7,837 units and 11,755 units (total 19,592 units); price reported $0.00 (derivative awards).
• Post-transaction beneficial ownership: not disclosed in the filing.
• Footnotes / material terms:
  • F1: These are market share/performance units that convert to common shares based on a payout factor tied to Total Return and relative Total Shareholder Return (rTSR). Total Return payout factor ranges from 80% to 225% (for the Total Return component). The rTSR floor can provide a minimum payout based on peer percentile: <50th = 0%, 50th–74.99th = 50%, ≥75th = 100%.
  • F2: Market share units cliff-vest on the third anniversary of the grant, subject to Board certification of performance results.
  • F3: Performance share units convert into one share of common stock upon distribution in Q1 2029, subject to Board certification.
• Filing includes Exhibit 24 (Power of Attorney). No 10b5-1 plan, tax withholding, or sale/transfer instructions are indicated.

Context These are performance- and time‑based compensation awards intended to align executive pay with long-term shareholder returns. Because they are derivative awards with multi-year performance/vesting conditions and no cash exchanged, they do not represent an immediate purchase or sale of stock.